ClinicalTrials.gov record
Co-administration of Olodaterol Respimat® and Tiotropium Handihaler®
ClinicalTrials.gov ID: NCT01696058
Public ClinicalTrials.gov record NCT01696058. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomised, Double Blind, Parallel Group Study to Assess the Efficacy and Safety of 12 Weeks of Once Daily, Orally Inhaled, Co-administration of Olodaterol 5µg (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) Compared to Once Daily, Orally Inhaled, Co-administration of Placebo (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) in Patients With Chronic Obstructive Pulmonary Disease (COPD)[ANHELTO TM 2]
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The overall objective of this study is to assess efficacy and safety of 12 weeks, once daily, orally inhaled co-administration of olodaterol 5 µg (delivered by the Respimat® Inhaler) and tiotropium (delivered by the Handihaler® as Spiriva Handihaler®), compared to tiotropium (Spiriva Handihaler®) monotherapy on lung function in patients with COPD.
Study identification
- NCT ID
- NCT01696058
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 1,137 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 40 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 31, 2012
- Primary completion
- Sep 30, 2013
- Completion
- Sep 30, 2013
- Last update posted
- Nov 24, 2014
2012 – 2013
United States locations
- U.S. sites
- 94
- U.S. states
- 34
- U.S. cities
- 85
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| 1222.52.02090 Boehringer Ingelheim Investigational Site | Anniston | Alabama | — | — |
| 1222.52.02046 Boehringer Ingelheim Investigational Site | Birmingham | Alabama | — | — |
| 1222.52.02014 Boehringer Ingelheim Investigational Site | Mobile | Alabama | — | — |
| 1222.52.02017 Boehringer Ingelheim Investigational Site | Montgomery | Alabama | — | — |
| 1222.52.02092 Boehringer Ingelheim Investigational Site | Anchorage | Alaska | — | — |
| 1222.52.02072 Boehringer Ingelheim Investigational Site | Chandler | Arizona | — | — |
| 1222.52.02063 Boehringer Ingelheim Investigational Site | Glendale | Arizona | — | — |
| 1222.52.02088 Boehringer Ingelheim Investigational Site | Peoria | Arizona | — | — |
| 1222.52.02012 Boehringer Ingelheim Investigational Site | Phoenix | Arizona | — | — |
| 1222.52.02006 Boehringer Ingelheim Investigational Site | Huntington Beach | California | — | — |
| 1222.52.02031 Boehringer Ingelheim Investigational Site | San Jose | California | — | — |
| 1222.52.02011 Boehringer Ingelheim Investigational Site | Torrance | California | — | — |
| 1222.52.02061 Boehringer Ingelheim Investigational Site | Boulder | Colorado | — | — |
| 1222.52.02054 Boehringer Ingelheim Investigational Site | Fort Collins | Colorado | — | — |
| 1222.52.02001 Boehringer Ingelheim Investigational Site | Hartford | Connecticut | — | — |
| 1222.52.02037 Boehringer Ingelheim Investigational Site | Norwalk | Connecticut | — | — |
| 1222.52.02055 Boehringer Ingelheim Investigational Site | Waterbury | Connecticut | — | — |
| 1222.52.02094 Boehringer Ingelheim Investigational Site | Clearwater | Florida | — | — |
| 1222.52.02022 Boehringer Ingelheim Investigational Site | Fort Lauderdale | Florida | — | — |
| 1222.52.02074 Boehringer Ingelheim Investigational Site | Orlando | Florida | — | — |
| 1222.52.02016 Boehringer Ingelheim Investigational Site | Ponte Verda | Florida | — | — |
| 1222.52.02084 Boehringer Ingelheim Investigational Site | Saint Petersberg | Florida | — | — |
| 1222.52.02043 Boehringer Ingelheim Investigational Site | Tampa | Florida | — | — |
| 1222.52.02009 Boehringer Ingelheim Investigational Site | Blue Ridge | Georgia | — | — |
| 1222.52.02048 Boehringer Ingelheim Investigational Site | Duluth | Georgia | — | — |
| 1222.52.02077 Boehringer Ingelheim Investigational Site | Gainsville | Georgia | — | — |
| 1222.52.02040 Boehringer Ingelheim Investigational Site | Rincon | Georgia | — | — |
| 1222.52.02024 Boehringer Ingelheim Investigational Site | O'Fallon | Illinois | — | — |
| 1222.52.02002 Boehringer Ingelheim Investigational Site | Muncie | Indiana | — | — |
| 1222.52.02008 Boehringer Ingelheim Investigational Site | Fort Mitchell | Kentucky | — | — |
| 1222.52.02025 Boehringer Ingelheim Investigational Site | Louisville | Kentucky | — | — |
| 1222.52.02089 Boehringer Ingelheim Investigational Site | New Orleans | Louisiana | — | — |
| 1222.52.02005 Boehringer Ingelheim Investigational Site | Baltimore | Maryland | — | — |
| 1222.52.02029 Boehringer Ingelheim Investigational Site | Columbia | Maryland | — | — |
| 1222.52.02036 Boehringer Ingelheim Investigational Site | Hollywood | Maryland | — | — |
| 1222.52.02015 Boehringer Ingelheim Investigational Site | Townson | Maryland | — | — |
| 1222.52.02034 Boehringer Ingelheim Investigational Site | North Dartmouth | Massachusetts | — | — |
| 1222.52.02003 Boehringer Ingelheim Investigational Site | Chelsea | Michigan | — | — |
| 1222.52.02020 Boehringer Ingelheim Investigational Site | Kalamazoo | Michigan | — | — |
| 1222.52.02047 Boehringer Ingelheim Investigational Site | Minneapolis | Minnesota | — | — |
| 1222.52.02049 Boehringer Ingelheim Investigational Site | Minneapolis | Minnesota | — | — |
| 1222.52.02079 Boehringer Ingelheim Investigational Site | Plymouth | Minnesota | — | — |
| 1222.52.02068 Boehringer Ingelheim Investigational Site | Chesterfield | Missouri | — | — |
| 1222.52.02028 Boehringer Ingelheim Investigational Site | St Louis | Missouri | — | — |
| 1222.52.02053 Boehringer Ingelheim Investigational Site | St Louis | Missouri | — | — |
| 1222.52.02050 Boehringer Ingelheim Investigational Site | Billings | Montana | — | — |
| 1222.52.02035 Boehringer Ingelheim Investigational Site | Henderson | Nevada | — | — |
| 1222.52.02030 Boehringer Ingelheim Investigational Site | Marlton | New Jersey | — | — |
| 1222.52.02071 Boehringer Ingelheim Investigational Site | Albuquerque | New Mexico | — | — |
| 1222.52.02064 Boehringer Ingelheim Investigational Site | Johnson City | New York | — | — |
| 1222.52.02087 Boehringer Ingelheim Investigational Site | New Windsor | New York | — | — |
| 1222.52.02091 Boehringer Ingelheim Investigational Site | Syracuse | New York | — | — |
| 1222.52.02076 Boehringer Ingelheim Investigational Site | Calabash | North Carolina | — | — |
| 1222.52.02010 Boehringer Ingelheim Investigational Site | Huntersville | North Carolina | — | — |
| 1222.52.02045 Boehringer Ingelheim Investigational Site | Raleigh | North Carolina | — | — |
| 1222.52.02038 Boehringer Ingelheim Investigational Site | Salisbury | North Carolina | — | — |
| 1222.52.02051 Boehringer Ingelheim Investigational Site | Shelby | North Carolina | — | — |
| 1222.52.02058 Boehringer Ingelheim Investigational Site | Tabor City | North Carolina | — | — |
| 1222.52.02013 Boehringer Ingelheim Investigational Site | Winston-Salem | North Carolina | — | — |
| 1222.52.02062 Boehringer Ingelheim Investigational Site | Cincinnati | Ohio | — | — |
| 1222.52.02039 Boehringer Ingelheim Investigational Site | Columbus | Ohio | — | — |
| 1222.52.02081 Boehringer Ingelheim Investigational Site | Columbus | Ohio | — | — |
| 1222.52.02093 Boehringer Ingelheim Investigational Site | Columbus | Ohio | — | — |
| 1222.52.02059 Boehringer Ingelheim Investigational Site | Oklahoma City | Oklahoma | — | — |
| 1222.52.02026 Boehringer Ingelheim Investigational Site | Medford | Oregon | — | — |
| 1222.52.02097 Boehringer Ingelheim Investigational Site | Medford | Oregon | — | — |
| 1222.52.02075 Boehringer Ingelheim Investigational Site | Philadelphia | Pennsylvania | — | — |
| 1222.52.02102 Boehringer Ingelheim Investigational Site | Philadelphia | Pennsylvania | — | — |
| 1222.52.02080 Boehringer Ingelheim Investigational Site | Pittsburgh | Pennsylvania | — | — |
| 1222.52.02100 Boehringer Ingelheim Investigational Site | Charleston | South Carolina | — | — |
| 1222.52.02096 Boehringer Ingelheim Investigational Site | Easley | South Carolina | — | — |
| 1222.52.02085 Boehringer Ingelheim Investigational Site | Greenville | South Carolina | — | — |
| 1222.52.02101 Boehringer Ingelheim Investigational Site | Greenville | South Carolina | — | — |
| 1222.52.02065 Boehringer Ingelheim Investigational Site | Hodges | South Carolina | — | — |
| 1222.52.02042 Boehringer Ingelheim Investigational Site | Myrtle Beach | South Carolina | — | — |
| 1222.52.02083 Boehringer Ingelheim Investigational Site | Rock Hill | South Carolina | — | — |
| 1222.52.02066 Boehringer Ingelheim Investigational Site | Spartanburg | South Carolina | — | — |
| 1222.52.02095 Boehringer Ingelheim Investigational Site | Spartanburg | South Carolina | — | — |
| 1222.52.02098 Boehringer Ingelheim Investigational Site | Union | South Carolina | — | — |
| 1222.52.02018 Boehringer Ingelheim Investigational Site | Brentwood | Tennessee | — | — |
| 1222.52.02086 Boehringer Ingelheim Investigational Site | Arlington | Texas | — | — |
| 1222.52.02044 Boehringer Ingelheim Investigational Site | Austin | Texas | — | — |
| 1222.52.02041 Boehringer Ingelheim Investigational Site | El Paso | Texas | — | — |
| 1222.52.02027 Boehringer Ingelheim Investigational Site | Fort Worth | Texas | — | — |
| 1222.52.02056 Boehringer Ingelheim Investigational Site | Houston | Texas | — | — |
| 1222.52.02007 Boehringer Ingelheim Investigational Site | San Antonio | Texas | — | — |
| 1222.52.02060 Boehringer Ingelheim Investigational Site | San Antonio | Texas | — | — |
| 1222.52.02078 Boehringer Ingelheim Investigational Site | Sugar Land | Texas | — | — |
| 1222.52.02082 Boehringer Ingelheim Investigational Site | Waco | Texas | — | — |
| 1222.52.02057 Boehringer Ingelheim Investigational Site | Midvale | Utah | — | — |
| 1222.52.02023 Boehringer Ingelheim Investigational Site | Richmond | Virginia | — | — |
| 1222.52.02069 Boehringer Ingelheim Investigational Site | Selah | Washington | — | — |
| 1222.52.02019 Boehringer Ingelheim Investigational Site | Tacoma | Washington | — | — |
| 1222.52.02099 Boehringer Ingelheim Investigational Site | Morgantown | West Virginia | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01696058, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 24, 2014 · Synced Sep 1, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01696058 live on ClinicalTrials.gov.